Evidence map›Paper›PMID 41646800›Full record

ArticlemedRxiv : the preprint server for health sciences2026

A Three-subtype Molecular model of Cervical Cancer: Multiple PI3K Pathway inhibitors suppress growth and cooperate with HPV-directed immunotherapy.

Hong Lou, David Langan, Nick Syracuse, Elizabeth A Murphy, Sojung Kim, Emma Robinson, Nicole M Rossi, Yi Xie, Sonam Tulsyan, Tawnjerae Joe and 5 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Hong LouCancer Genetics Research Laboratory, Division of Cancer Epidemiology and Genetics, Frederick National Laboratory for Cancer Research, Gaithersburg, MD USA.
David LanganNexImmune, Gaithersburg, MD USA.
Nick SyracuseLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Gaithersburg, MD USA.
Elizabeth A MurphyCaris Life Sciences, Phoenix, AZ, USA.
Sojung KimNexImmune, Gaithersburg, MD USA.
Emma RobinsonCancer Genetics Research Laboratory, Division of Cancer Epidemiology and Genetics, Frederick National Laboratory for Cancer Research, Gaithersburg, MD USA.
Nicole M RossiLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Gaithersburg, MD USA.
Yi XieLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Gaithersburg, MD USA.
Sonam TulsyanLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Gaithersburg, MD USA.
Tawnjerae JoeLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Gaithersburg, MD USA.
Isabel RodriguezLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Gaithersburg, MD USA.
Nina RaoLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Gaithersburg, MD USA.
Matthew R OberleyCaris Life Sciences, Phoenix, AZ, USA.
Mathias OelkeNexImmune, Gaithersburg, MD USA.
Michael DeanLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Gaithersburg, MD USA.ORCID 0000-0003-2234-0631

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Cervical cancer is caused by human papillomavirus (HPV) infections; however, there are no molecularly defined subtypes, and few approved targeted therapies. We defined molecular subtypes and tested targeted agents. Methods: Public datasets were analyzed; cell lines were treated with drugs; and donor T cells and their proliferation were measured. Results: We define three molecular subtypes: I, Wild type for Conclusions: Our study revealed molecular inhibitors targeting mutant

Indexed as

Cervical Cancerclinical outcomesImmune Checkpoint InhibitorImmunotherapyMajor histocompatibility complex - MHCreal-world dataVirology

Identifiers

PMID41646800
PMCPMC12870545

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.